Which company produces Tremelimumab?

Tremelimumab (Tremelimumab) is an innovative immune checkpoint inhibitor. Its development and production are handled by AstraZeneca AB, a world-renowned pharmaceutical company. AstraZeneca has rich experience and leading technology in the field of biopharmaceuticals, and has long been focused on the research and development of anti-cancer immunological drugs. As one of its anti-CTLA-4 monoclonal antibody products, temsitumumab regulates the tumor microenvironment by targeting immune checkpoints and improves the patient's own immune system's ability to recognize and attack tumors.

From the perspective of production technology, temsitumumab is a fully humanized antibodyIgG2 monoclonal antibody, which is produced from mammalian cell lines through recombinant DNA technology. The pharmaceutical process requires highly precise protein expression and purification processes to ensure the stability, activity and safety of the drug. Due to its complex biopharmaceutical processes, there are currently only a few capable large pharmaceutical companies in the world that can undertake the production of original drugs. AstraZeneca is not only responsible for the research and development of temsitumumab, but also controls its production standards and quality management system to ensure the safety and effectiveness of the drug in clinical use.

In addition, AstraZeneca has clinical and production bases in many countries around the world, so temsitumumab can enter the international market, including the United States, Europe and parts of Asia. In mainland China, the original drug is not yet on the market, but Hong Kong and some overseas markets have begun to provide the drug. AstraZeneca's brand and technical background provide strong guarantee for the quality and clinical credibility of temsitumumab, and also give patients and doctors more confidence when choosing immunotherapy options.

In general, the original drug of temsitumumab is produced by AstraZeneca (ASTRAZENECA AB), which has world-class R&D and production technology background and plays an important role in cancers such as hepatocellular carcinoma and non-small cell lung cancer (NSCLC). Its fully humanized monoclonal antibody characteristics, strict production processes and global regulatory standards have given it high recognition in the field of immuno-oncology treatment.

Reference: https://www.drugs.com/mtm/tremelimumab.html